Piper Sandler Maintains Overweight on Jazz Pharmaceuticals, Lowers Price Target to $166
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst David Amsellem maintains an Overweight rating on Jazz Pharmaceuticals (NASDAQ:JAZZ) but lowers the price target from $188 to $166.
August 01, 2024 | 5:08 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Piper Sandler analyst David Amsellem maintains an Overweight rating on Jazz Pharmaceuticals but lowers the price target from $188 to $166.
The lowered price target from $188 to $166 suggests a less optimistic outlook for Jazz Pharmaceuticals, which could lead to a short-term negative impact on the stock price despite the maintained Overweight rating.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100